Abstract
This publication includes existing experiences, lessons learned, challenges and future developments in the production of Ac-225 radiopharmaceuticals for Targeted Alpha Therapy (TAT). This publication will be utilized by all involved professionals in the Targeted Alpha Therapy field, specifying ideal production, formulation, quality control and regulatory aspects of various Ac-225 radiopharmaceuticals. The intended audience also includes radiochemists, radiopharmacists, and medical physicists.
Publisher
INTERNATIONAL ATOMIC ENERGY AGENCY
Reference128 articles.
1. [1] KIM, YS., BRECHBIEL, M.W., An overview of targeted alpha therapy, Tumour
2. Biol. 33 (2012) 573. 10.1007/s13277-011-0286-y.
3. [2] TAFRESHI, NK., et al., Development of targeted alpha particle therapy for solid
4. tumours, Molecules 24 (2019) 4314. 10.3390/molecules24234314.
5. [3] MORGENSTERN, A., APOSTOLIDIS, C., BRUCHERTSEIFER F., Supply and